Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 774-782

  Gómez Outes, Antonio ^a   Terleira Fernández, Ana Isabel ^b,c   Lecumberri, Ramón ^d   Suárez Gea, M Luisa ^a   Vargas Castrillón, Emilio ^b,c  

^a Parque Empresarial Las Mercedes   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; HEPARIN; RIVAROXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

AGE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; GENDER; HUMAN; KIDNEY FUNCTION; LUNG EMBOLISM; META ANALYSIS; MORBIDITY; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HEMORRHAGE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84908215675     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.06.020     Document Type: Article

References (39)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914-8.
2. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl.):e419S-94S.
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl.):160S-98S.
4. Gómez-Outes A, Suárez-Gea ML, Calvo-Rojas G, Lecumberri R, Rocha E, Pozo-Hernández C, et al. Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol 2012;9:83-104.
5. European Medicines Agency. Pradaxa ® - summary of product characteristics. Accessed at www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000829/WC500041059.pdf; 2013 . [on 2 November 2013].
6. European Medicines Agency. Xarelto ® - summary of product characteristics. Accessed at www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000944/WC500057108.pdf; 2013 . [on 2 November 2013].
7. European Medicines Agency. Eliquis ® - summary of product characteristics. Accessed at www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002148/WC500107728.pdf; 2013 . [on 2 November 2013].
8. Ahrens I, Bode C. Oral anticoagulation with edoxaban. Focus on current phase III clinical development. Hamostaseologie 2012;32:212-5.
9. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-9.
10. van Gogh Investigators, Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094-104.
11. Schulman S, Kearon C. Defi nition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
12. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
14. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
15. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
18. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.1; 2011. http://tech.cochrane.org/revman/about-revman-5 [Copenhagen].
19. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
20. Schulman S, Kakkar AK, Goldhaber SZ, Schellong SM, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72.
21. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
22. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
23. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
24. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.
25. Boehringer Ingelheim. Trial synopsis 1160.53 (RE-COVER). Accessed at http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com-EN/results/1160/1160.53-U09-1400.pdf . [on 9 November 2013].
26. Boehringer Ingelheim. Trial synopsis 1160.46 (RE-COVER II). Accessed at http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com-EN/results/1160/1160.46-U11-2298-01.pdf . [on 9 November 2013].
27. Bayer HealthCare. Trial synopsis 11702a (EINSTEIN-DVT). Accessed at http://trialfinder.bayerscheringpharma.de/html/pdf/11702a-Study-Synopsis-CTP.pdf . [on 9 November 2013].
28. Bayer HealthCare. Trial synopsis 11702b (EINSTEIN-PE). Accessed at http://trialfinder.bayerscheringpharma.de/html/pdf/11702b-Study-Synopsis-CTP-2012-11-06.pdf . [on 9 November 2013].
29. Committee for Medicinal Products for Human Use (CHMP). Public Assessment Report on Xarelto (Rivaroxaban). Procedure No. EMEA/H/C/000944/X/0010. Document EMA/CHMP/301607/2011. Accessed at http://www.ema.europa.eu . [on 9 November 2013].
30. Committee for Medicinal Products for Human Use (CHMP). Public Assessment Report on Xarelto (Rivaroxaban). Procedure No. EMEA/H/C/000944/II/0018. Document: EMA/56019/2013. Accessed at http://www.ema.europa.eu . [on 9 November 2013].
31. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112:2242-7.
32. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007;116:180-7.
33. Botticelli InvestigatorsWriting Committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-8.
34. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498.
35. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants compared with vitamin K-antagonists in the treatment of acute symptomatic venous thromboembolism- a systematic review and meta-analysis. J Thromb Haemost 2014;12:320-8.
36. Plichart M, Berrut G, Maubourguet N, Jeandel C, Emeriau JP, Ankri J, et al. Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG). Drugs Aging 2013;30:1019-28.
37. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013;11:56-70.
38. Erkens PM, ten Cate H, Büller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One 2012;7:e42269.
39. Fauchier L, Taillandier S. Geographic variations in the quality of oral anticoagulation with vitamin k antagonists in the era of new anticoagulants. J Am Heart Assoc 2013;2:e000088.